Valerie Lee

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Lei Zheng · 7 shared papers, 2017–2026 · strength 0.90
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conven… DOI 10.3389/fonc.2023.1250136↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
2. Daniel A. Laheru · 7 shared papers, 2017–2026 · strength 0.90
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conven… DOI 10.3389/fonc.2023.1250136↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
3. Dung Thi Le · 6 shared papers, 2017–2026 · strength 0.74
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conven… DOI 10.3389/fonc.2023.1250136↗
   • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
4. Amol Kumar Narang · 6 shared papers, 2017–2026 · strength 0.70
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
5. Elizabeth M. Jaffee · 4 shared papers, 2019–2026 · strength 0.59
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Current Status of Immunotherapies for Treating Pancreatic Cancer. DOI 10.1007/s11912-019-0811-5↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
6. Ana De Jesus‐Acosta · 5 shared papers, 2017–2023 · strength 0.54
   • Paper Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conven… DOI 10.3389/fonc.2023.1250136↗
   • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
   • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
7. Robert A. Anders · 4 shared papers, 2021–2026 · strength 0.54
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
8. Joseph M. Herman · 4 shared papers, 2017–2026 · strength 0.52
   • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
9. Jin Peng He · 5 shared papers, 2017–2024 · strength 0.50
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
   • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
10. Michael Jon Pishvaian · 3 shared papers, 2022–2026 · strength 0.50
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
    • Paper Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conven… DOI 10.3389/fonc.2023.1250136↗
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
11. Ding Ding · 3 shared papers, 2021–2026 · strength 0.38
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
12. Richard Andrew Burkhart · 3 shared papers, 2021–2026 · strength 0.38
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
13. Arsen Osipov · 2 shared papers, 2024–2026 · strength 0.36
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
14. Amy Hacker‐Prietz · 4 shared papers, 2017–2022 · strength 0.35
    • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
15. William R. Burns · 3 shared papers, 2021–2022 · strength 0.30
    • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
16. Matthew John Weiss · 3 shared papers, 2017–2022 · strength 0.25
    • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
    • Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
17. Ross C. Donehower · 3 shared papers, 2017–2022 · strength 0.23
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
    • Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
18. Nilofer Saba Azad · 3 shared papers, 2017–2022 · strength 0.23
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
    • Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
19. Elliot K. Fishman · 3 shared papers, 2017–2022 · strength 0.23
    • Paper RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. DOI 10.1200/po.21.00404↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
    • Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
20. Eric Scott Christenson · 1 shared paper, 2026 · strength 0.20
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
21. MS, PA-C Amy Hacker-Prietz · 1 shared paper, 2026 · strength 0.20
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
22. Hao Wang · 1 shared paper, 2026 · strength 0.20
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
23. Kelly J. Lafaro · 1 shared paper, 2026 · strength 0.20
    • Paper The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced p… DOI 10.1038/s41467-026-69294-3↗
24. Christopher L. Wolfgang · 2 shared papers, 2021–2022 · strength 0.20
    • Paper High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally … DOI 10.1002/cam4.4527↗
    • Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
25. Amol Gupta · 1 shared paper, 2023 · strength 0.19
    • Paper Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conven… DOI 10.3389/fonc.2023.1250136↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.